5:34 PM
 | 
Mar 18, 2009
 |  BC Extra  |  Clinical News

Herceptin meets gastric cancer endpoint

Roche (SIX:ROG) said interim data showed that first-line Herceptin trastuzumab plus chemotherapy met the primary endpoint of significantly increasing overall survival vs. chemotherapy alone...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >